keyword
MENU ▼
Read by QxMD icon Read
search

pneumococcal vaccine adverse effect

keyword
https://www.readbyqxmd.com/read/28467293/a-randomized-open-label-study-to-investigate-the-effect-of-belimumab-on-pneumococcal-vaccination-in-patients-with-active-autoantibody-positive-systemic-lupus-erythematosus
#1
W Chatham, A Chadha, J Fettiplace, C Kleoudis, D Bass, D Roth, D Gordon
Objective Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. Methods This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United States. Patients were randomized (7:9) to receive a 23-valent pneumococcal vaccination four weeks prior to (pre-belimumab cohort) or 24 weeks after (belimumab-concurrent cohort) commencing four-weekly belimumab 10 mg/kg intravenous treatment plus standard systemic lupus erythematosus therapy...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28429115/comparison-of-the-tolerability-of-newly-introduced-childhood-vaccines-in-the-netherlands
#2
Jeanet M Kemmeren, Nicoline At van der Maas, Hester E de Melker
In 2011, the 7-valent conjugated pneumococcal vaccine (PCV7) was replaced by the 10-valent vaccine (PCV10) and universal hepatitis B vaccination has been introduced in the Netherlands. A questionnaire study was conducted to assess the tolerability of DTaP-IPV-Hib + PCV7 (PCV7-cohort), DTaP-IPV-Hib + PCV10 (PCV10-cohort), and DTaP-IPV-Hib-HepB + PCV10 (HepB-cohort). Parents were asked to report in questionnaires local reactions and systemic adverse events (AEs) before and after vaccination of their infant at 2, 3, 4, and 11 months of age...
April 20, 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28352933/erythema-multiforme-following-pneumococcal-vaccination
#3
Alexandra Monastirli, Efstathia Pasmatzi, George Badavanis, Dionysios Tsambaos
Erythema multiforme (EM) is an acute and usually self-limited immune-mediated mucocutaneous disorder that is a hypersensitivity reaction to drugs, infections, and vaccines. Clinically, it is characterized by maculopapular, target-like lesions symmetrically distributed on the extremities (minor form) or additionally affecting one or more mucous membranes and causing epidermal detachment involving < 10% of the total body surface area (major form). We report a novel association between pneumococcal vaccination and the development of EM in a 2...
March 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/28242152/-post-licensure-safety-surveillance-for-prevenar-13-%C3%A2-in-france
#4
M-S Agier, S Marchand, N Paret, S Gautier, A-P Jonville-Béra
OBJECTIVE: To describe the profile and the incidence of adverse events (AEs) reported with Prevenar 13(®) since its commercialization. METHOD: Analysis of all adverse events reported with Prevenar 13(®) in France between 1st July 2010 and 31 October 2014. RESULTS: In 4 years and 4 months, 376 AEs, including 252 severe (67%), were recorded, 83 of which occurred following an injection of Prevenar 13(®) alone: 39 cutaneous AEs, 16 neurological AEs, four cases of collapse or shock, nine cases of fever, and one of thrombocytopenia...
May 2017: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/28145151/factors-associated-with-influenza-and-pneumococcal-vaccine-uptake-among-rheumatoid-arthritis-patients-in-denmark-invited-to-participate-in-a-pneumococcal-vaccine-trial-immunovax_ra
#5
Mtt Nguyen, H Lindegaard, O Hendricks, N Friis-Møller
OBJECTIVE: This study investigates predictors of influenza and pneumococcal vaccine coverage among rheumatoid arthritis (RA) patients, and explores possible differences according to type of RA therapy. METHOD: RA patients from two clinics in the region of Southern Denmark were informed about the survey during scheduled follow-up visits. The questionnaire included questions concerning previous influenza and pneumococcal vaccine uptake, attitudes about vaccination, and socio-demographic factors...
February 1, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28133957/efficacy-and-safety-of-vaccination-in-pediatric-patients-with-systemic-inflammatory-rheumatic-diseases-a-systematic-review-of-the-literature
#6
Sandra Sousa, Ana Catarina Duarte, Inês Cordeiro, Joana Ferreira, Maria João Gonçalves, Tiago Meirinhos, Teresa Martins Rocha, Vasco C Romão, Maria José Santos
INTRODUCTION: Children and adolescents with systemic rheumatic diseases have an increased risk of infections. Although some infections are vaccine-preventable, immunization among patients with juvenile rheumatic diseases is suboptimal, partly due to some doubts that still persist regarding its efficacy and safety in this patient population. OBJECTIVES: To review the available evidence regarding the immunological response and the safety of vaccination in children and adolescents with systemic inflammatory rheumatic diseases (SIRD)...
January 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28120848/nanogel-based-nasal-ghrelin-vaccine-prevents-obesity
#7
T Azegami, Y Yuki, S Sawada, M Mejima, K Ishige, K Akiyoshi, H Itoh, H Kiyono
Obesity is associated with multiple comorbidities such as cardiovascular diseases and has a huge economic impact on the health-care system. However, the treatment of obesity remains insufficient in terms of efficacy, tolerability, and safety. Here we created a nasal vaccine against obesity for the first time. To avoid the injectable administration-caused pain and skin-related adverse event, we focused on the intranasal route of antigen delivery. We developed a vaccine antigen (ghrelin-PspA (pneumococcal surface protein A)), which is a recombinant fusion protein incorporating ghrelin, a hormone that stimulates food intake and decreases energy expenditure, and PspA, a candidate of pneumococcal vaccine as a carrier protein...
January 25, 2017: Mucosal Immunology
https://www.readbyqxmd.com/read/28116747/pneumococcal-vaccines-for-preventing-pneumonia-in-chronic-obstructive-pulmonary-disease
#8
REVIEW
Julia Ae Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood-Baker
BACKGROUND: People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs. OBJECTIVES: To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD. SEARCH METHODS: We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms...
January 24, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27887596/effectiveness-immunogenicity-and-safety-of-23-valent-pneumococcal-polysaccharide-vaccine-revaccinations-in-the-elderly-a-systematic-review
#9
Cornelius Remschmidt, Thomas Harder, Ole Wichmann, Christian Bogdan, Gerhard Falkenhorst
BACKGROUND: In many industrialized countries routine vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) is recommended to prevent pneumococcal disease in the elderly. However, vaccine-induced immunity wanes after a few years, and there are controversies around revaccination with PPSV-23. Here, we systematically assessed the effectiveness and safety of PPSV-23 revaccination. METHOD: We conducted a systematic literature review in MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials from inception to June 2015...
November 25, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27876197/vaccination-of-special-populations-protecting-the-vulnerable
#10
REVIEW
Mark Doherty, Ruprecht Schmidt-Ott, Jose Ignacio Santos, Lawrence R Stanberry, Annika M Hofstetter, Susan L Rosenthal, Anthony L Cunningham
One of the strategic objectives of the 2011-2020 Global Vaccine Action Plan is for the benefits of immunisation to be equitably extended to all people. This approach encompasses special groups at increased risk of vaccine-preventable diseases, such as preterm infants and pregnant women, as well as those with chronic and immune-compromising medical conditions or at increased risk of disease due to immunosenescence. Despite demonstrations of effectiveness and safety, vaccine uptake in these special groups is frequently lower than expected, even in developed countries with vaccination strategies in place...
December 20, 2016: Vaccine
https://www.readbyqxmd.com/read/27780630/effect-of-tdap-when-administered-before-with-or-after-the-13-valent-pneumococcal-conjugate-vaccine-coadministered-with-the-quadrivalent-meningococcal-conjugate-vaccine-in-adults-a-randomised-controlled-trial
#11
M Tashani, M Alfelali, O Barasheed, A S Alqahtani, L Heron, M Wong, H Rashid, R Booy
Sequential or co-administration of vaccines has potential to alter the immune response to any of the antigens. Existing literature suggests that prior immunisation of tetanus/diphtheria-containing vaccines can either enhance or suppress immune response to conjugate pneumococcal or meningococcal vaccines. We examined this interaction among adult Australian travellers before attending the Hajj pilgrimage 2014. We also investigated tolerability of these vaccines separately and concomitantly. We randomly assigned each participant to one of three vaccination schedules...
October 22, 2016: Vaccine
https://www.readbyqxmd.com/read/27753887/ish-nia-os-02-attenuation-of-hypertension-by-less-invasive-intranasal-vaccination-against-angiotensin-ii-type-1-receptor-in-spontaneously-hypertensive-rats
#12
Tatsuhiko Azegami, Yoshikazu Yuki, Kaori Hayashi, Mari Nakamura, Akihito Hishikawa, Hiroshi Kiyono, Hiroshi Itoh
OBJECTIVE: Previous studies have shown that injectable vaccines against renin-angiotensin system may be effective for the treatment of hypertension, but these injectable vaccines often cause local skin reactions and soreness at the injection site. The aim of this study was to develop a new non-injectable vaccine against angiotensin II type 1 receptor (AT1R) and examine its effect on blood pressure. DESIGN AND METHOD: The peptide, seven-amino-acid sequence from second extracellular loop of rat AT1R was synthesized and then conjugated with pneumococcal surface protein A (PspA) as a carrier protein for the nasal vaccination...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27648207/influenza-and-pneumococcal-vaccination-in-hematological-malignancies-a-systematic-review-of-efficacy-effectiveness-and-safety
#13
REVIEW
Giuseppe La Torre, Alice Mannocci, Vittoria Colamesta, Valeria D'Egidio, Cristina Sestili, Antonietta Spadea
BACKGROUND: The risk of getting influenza and pneumococcal disease is higher in cancer patients, and serum antibody levels tend to be lower in patients with hematological malignancy. OBJECTIVE: To assess flu and pneumococcal vaccinations efficacy, effectiveness, and safety in onco-hematological patients. METHODS: Two systematic reviews and possible meta-analysis were conducted to summarize the results of all primary study in the scientific literature about the flu and pneumococcal vaccine in onco-hematological patients...
2016: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/27643233/ish-nia-os-02-attenuation-of-hypertension-by-less-invasive-intranasal-vaccination-against-angiotensin-ii-type-1-receptor-in-spontaneously-hypertensive-rats
#14
Tatsuhiko Azegami, Yoshikazu Yuki, Kaori Hayashi, Mari Nakamura, Akihito Hishikawa, Hiroshi Kiyono, Hiroshi Itoh
OBJECTIVE: Previous studies have shown that injectable vaccines against renin-angiotensin system may be effective for the treatment of hypertension, but these injectable vaccines often cause local skin reactions and soreness at the injection site. The aim of this study was to develop a new non-injectable vaccine against angiotensin II type 1 receptor (AT1R) and examine its effect on blood pressure. DESIGN AND METHOD: The peptide, seven-amino-acid sequence from second extracellular loop of rat AT1R was synthesized and then conjugated with pneumococcal surface protein A (PspA) as a carrier protein for the nasal vaccination...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27605588/distance-to-health-services-modifies-the-effect-of-an-11-valent-pneumococcal-vaccine-on-pneumonia-risk-among-children-less-than-2-years-of-age-in-bohol-philippines
#15
Elisabeth Dowling Root, Marilla Lucero, Hanna Nohynek, Rebecca Stubbs, Veronica Tallo, Socorro P Lupisan, Diozele M Sanvictores, Leilani T Nillos, Eric A F Simões
BACKGROUND: Both vaccine trials and surveillance studies typically use passive surveillance systems to monitor study outcomes, which may lead to under-reporting of study outcomes in areas with poor access to care. This detection bias can have an adverse effect on conventional estimates of pneumonia risk derived from vaccine trials. METHODS: We conducted a secondary analysis of a randomized, placebo-controlled, double-blind vaccine trial that examined the efficacy of an 11-valent pneumococcal vaccine (PCV) among children less than 2 years of age in Bohol, Philippines...
September 7, 2016: International Journal of Epidemiology
https://www.readbyqxmd.com/read/27576076/optimizing-seroprotection-against-pneumococcus-in-children-with-nephrotic-syndrome-using-the-13-valent-pneumococcal-conjugate-vaccine
#16
Laure F Pittet, Klara M Posfay-Barbe, Hassib Chehade, Christoph Rudin, Alexandra Wilhelm-Bals, Maria Rodriguez, Claire-Anne Siegrist, Paloma Parvex
BACKGROUND: Infections are among the main life-threatening complications in patients with nephrotic syndrome (NS), in particular with Streptococcus pneumoniae, the first cause of bacterial peritonitis and sepsis in these patients. This study aims to evaluate the baseline seroprotection of NS patients against S. pneumoniae, and immunize them with the 13-valent pneumococcal conjugate vaccine (PCV13) regardless of disease activity and previous immunization history, in order to evaluate the immunogenicity, safety profile, and effect of NS treatment on vaccine responses...
September 22, 2016: Vaccine
https://www.readbyqxmd.com/read/27541270/effects-of-prophylactic-ibuprofen-and-paracetamol-administration-on-the-immunogenicity-and-reactogenicity-of-the-10-valent-pneumococcal-non-typeable-haemophilus-influenzae-protein-d-conjugated-vaccine-phid-cv-co-administered-with-dtpa-combined-vaccines-in-children
#17
Oana Falup-Pecurariu, Sorin C Man, Mihai L Neamtu, Gratiana Chicin, Ginel Baciu, Carmen Pitic, Alexandra C Cara, Andrea E Neculau, Marin Burlea, Ileana L Brinza, Cristina N Schnell, Valentina Sas, Valeriu V Lupu, Nancy François, Kristien Swinnen, Dorota Borys
Prophylactic paracetamol administration impacts vaccine immune response; this study ( www.clinicaltrials.gov : NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania (November 2010-December 2012), healthy infants were randomized 3:3:3:1:1:1 to prophylactically receive immediate, delayed or no ibuprofen (IIBU, DIBU, NIBU) or paracetamol (IPARA, DPARA, NPARA) after each of 3 primary doses (PHiD-CV at age 3/4/5 months co-administered with DTPa-HBV-IPV/Hib at 3/5 and DTPa-IPV/Hib at 4 months) or booster dose (PHiD-CV and DTPa-HBV-IPV/Hib; 12-15 months)...
March 4, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27155493/immunogenicity-and-safety-of-a-second-administration-of-13-valent-pneumococcal-conjugate-vaccine-5-years-after-initial-vaccination-in-adults-50-years-and-older
#18
Robert W Frenck, Anne Fiquet, Alejandra Gurtman, Martin van Cleeff, Matthew Davis, John Rubino, William Smith, Vani Sundaraiyer, Mohinder Sidhu, Emilio A Emini, William C Gruber, Daniel A Scott, Beate Schmoele-Thoma
BACKGROUND: Vaccination effectively reduces invasive disease and pneumonia caused by Streptococcus pneumoniae. However, waning antibody titers and the ability of revaccination to boost titers in older adults have been concerns. A study to describe antibody persistence after vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) and response to revaccination 5 years after the initial dose was conducted. METHODS: Pneumococcal vaccine-naive subjects aged 50-59 years were randomized and vaccinated with PCV13 plus trivalent inactivated influenza vaccine concomitantly or 1 month apart, then revaccinated with PCV13 five years later...
June 24, 2016: Vaccine
https://www.readbyqxmd.com/read/27149114/safety-and-immunogenicity-of-a-single-dose-23-valent-pneumococcal-polysaccharide-vaccine-in-russian-subjects
#19
Karen Ciprero, Kirill A Zykov, Nikolay I Briko, Tulin Shekar, Tina M Sterling, Elizaveta Bitieva, Jon E Stek, Luwy Musey
Pneumococcal infection is a major cause of pneumonia, bacteremia, and meningitis. Incidence of pneumococcal disease (PD) varies worldwide. The 23-valent pneumococcal polysaccharide vaccine (PPV23) displays an acceptable safety profile and has been demonstrated cost-effective in reducing burden of PD. METHODS: Approximately 100 subjects from the Russian Federation who were either 2 to 49 y of age with increased risk for PD or ≥50 years of age were enrolled into the study (NCT01734239) to receive a single dose of PPV23 administered intramuscularly...
August 2, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27093162/a-randomized-prospective-study-of-pediatric-patients-with-community-acquired-pneumonia-treated-with-ceftaroline-versus-ceftriaxone
#20
Christopher R Cannavino, Agnes Nemeth, Bartosz Korczowski, John S Bradley, Tanya O'Neal, Alena Jandourek, H David Friedland, Sheldon L Kaplan
BACKGROUND: Community-acquired bacterial pneumonia (CABP) remains a major infection among children, despite the use of pneumococcal vaccination. Ceftaroline fosamil is a broad-spectrum cephalosporin antibiotic with activity against many bacteria, including Streptococcus pneumoniae (both penicillin-nonsusceptible and multidrug-resistant strains) and Staphylococcus aureus (including methicillin-resistant S. aureus). This article describes the safety, tolerability, and effectiveness of ceftaroline fosamil in the treatment of pediatric patients hospitalized with CABP, from a randomized, active-controlled, observer-blinded clinical study (registration number NCT01530763)...
July 2016: Pediatric Infectious Disease Journal
keyword
keyword
96756
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"